10x Genomics Reports First Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
10x Genomics (TXG) Misses Q1 EPS by 10c; Offers FY23 Revenue Guidance
May 3, 2023 4:37 PM EDT10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.44), $0.10 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $134.3 million versus the consensus estimate of $129.24 million.
GUIDANCE:
10x Genomics sees FY2023 revenue of $590-610 million, versus the consensus... More
